Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of secukinumab compared to placebo in patients
that have moderate to severe, chronic, plaque-type psoriasis.